This month is extremely busy for Porsolt as we again take to the road to participate in two key international conferences, showcasing our recognized expertise and capabilities in the drug development process.
We will be exhibiting at the Society for Neuroscience meeting (#SfN22) taking place in San Diego (Nov 12 -16). Please come and meet with David Pushett, Kendall Walker PhD., Sabrina Djemmali, and Elise Esneault at Porsolt’s booth #2825. We are also presenting two exciting abstracts: “Human iPSC microglia for assessing new treatments in neurological diseases”, describing a novel translational model that can be used to study neuroinflammation, a crucial hallmark of neurodegenerative disorders in humans, and “Screening cascade for the evaluation of new anti-epileptic drug candidates”, confirming the importance of testing compounds across variety of models to assess anti-convulsant efficacy.
Porsolt is also attending the American College of Toxicology meeting (#ACTox2022), taking place in Denver (Nov 13 -16). Please come and visit Guillaume Froget and Sebastien Breche at Porsolt’s booth #134, to discuss your safety pharmacology and non-regulatory toxicology needs. We are also presenting a stimulating abstract entitled “In vitro predictive toxicity screening assays during early stage drug development: Case study data for the validity of 2D and 3D models” highlighting the important role of different models used for in vitro predictive toxicology.
Please don’t hesitate to contact us (email@example.com) to schedule a meeting to learn more about our growing capabilities, or visit our website for more information www.porsolt.com.